This article was originally published in The Gray Sheet
Begins shipment of its ImmunoCard for detection of Clostridium difficile on Feb. 1 after receiving marketing clearance from FDA on Jan. 27. The test, which is the seventh ImmunoCard to be brought to market, lists for between $10 and $15 per test. Meridian licenses the ImmunoCard technology from Disease Detection International ("The Gray Sheet" May 6, 1991, In Brief).
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.